INTEG Stock Price, News & Analysis

integ

Company Description

Integrum (publ) is a pioneering medical technology company based in Sweden, listed on NASDAQ First North Growth Market under the symbol INTEG. The company specializes in the development and commercialization of the OPRA™ Implant System, a groundbreaking solution for amputees. Recently, Integrum secured full funding from the US Department of Defense to conduct a clinical study on transtibial amputations at the Walter Reed National Military Medical Center. This study, once completed, will provide valuable data for future regulatory processes and expansion of the OPRA™ Implant System. Led by CEO Rickard Brånemark, Integrum is dedicated to revolutionizing amputee care and improving the lives of individuals worldwide.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

- %

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

Latest News

View All

29 days ago

0.00%

Integrum implements new compensation package for its CEO

March 18, 2025

0.00%

Integrum's OPRA™ Implant System demonstrates superior treatment outcomes in two-year follow-up study by Walter Reed National Military Medical Center

February 23, 2024

0.00%

Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation

earnings

February 1, 2024

0.00%

Integrum has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine

December 20, 2023

0.00%

Integrum establishes Center of Excellence in Ukraine

November 13, 2023

0.00%

Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data

clinical trial

SEC Filings

View All

No SEC filings available for INTEG.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is Integrum known for?

Integrum (publ) is known for its pioneering work in developing and commercializing the innovative OPRA™ Implant System for amputees.

What recent achievement did Integrum announce?

Integrum recently secured full funding from the US Department of Defense to conduct a clinical study on transtibial amputations.

Who will be performing the clinical study on transtibial amputations?

The study will be performed by top surgeons at the Walter Reed National Military Medical Center in Bethesda, Maryland.

How will Integrum use the data from the clinical study?

Integrum will utilize the data obtained from the clinical study to support any future regulatory processes and enhance the OPRA™ Implant System.

What is the goal of Integrum's CEO, Rickard Brånemark?

CEO Rickard Brånemark is committed to broadening the use of the OPRA™ Implant System to improve the lives of as many amputees as possible.

Who is the Certified Adviser for Integrum?

Erik Penser Bank serves as the Certified Adviser for Integrum.

When will Integrum's quarterly report for August - October 2023 be published?

The quarterly report will be published on December 4, 2023.

What is the expected revenue for Q2 at Integrum?

The revenue for Q2 is expected to be at 27.5 MSEK, representing a 36.2% increase compared to the previous year.

What is the significance of Integrum's OPRA™ Implant System in Ukraine?

Integrum's innovative implant system provides a superior option for amputees in Ukraine, especially following the recent conflict.

Where can I access the webcast presentation of Integrum's third quarter 2023/24 results?

The webcast will be available at https://www.finwire.tv/webcast/integrum/q3-presentation-2023/.